Immune begins Phase I/II of Ceplene in CMML

Immune Pharmaceuticals Inc. (NASDAQ:IMNP; SSE:IMNP) began a Phase I/II trial to evaluate twice-daily 0.5 mg subcutaneous Ceplene histamine dihydrochloride plus low-dose IL-2 in 15 patients with chronic myelomonocytic leukemia (CMML).

Patients will receive Ceplene with or without IL-2 for 3 consecutive weeks of a 6-week cycle for 4 cycles, after which patients can continue treatment for 3 consecutive weeks of a 9-week cycle for 6 additional cycles...